
It’s not known why a percentage of MS patients don’t respond to the drug interferon-β. Knowing more about this phenomenon has the potential to 1) improve drug choice strategies for…
It’s not known why a percentage of MS patients don’t respond to the drug interferon-β. Knowing more about this phenomenon has the potential to 1) improve drug choice strategies for…
Ultimately, we want our biomarker development work to enable faster and more accurate MS diagnosis and to improve disease progression assessment. These articles (here and here) in Multiple Sclerosis and…
For women with MS, deciding if and when to become pregnant and how to manage their disease before, during, and after pregnancy can be fraught with uncertainty. A recent editorial…
Want an excellent scientific review on how MS involves immune system dysfunction? This review in Nature Reviews: Immunology is it!
One the biggest challenges to correctly diagnosing MS is the wide array of symptoms that it can produce. Our work in developing biomarkers aims to eliminate the uncertainty by providing…